AR045783A1 - Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide - Google Patents

Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide

Info

Publication number
AR045783A1
AR045783A1 ARP040103356A ARP040103356A AR045783A1 AR 045783 A1 AR045783 A1 AR 045783A1 AR P040103356 A ARP040103356 A AR P040103356A AR P040103356 A ARP040103356 A AR P040103356A AR 045783 A1 AR045783 A1 AR 045783A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
inflammatory drug
active ingredient
composition including
steroid anti
Prior art date
Application number
ARP040103356A
Other languages
English (en)
Inventor
Nigel Boughton-Smith
Simon Cruwys
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR045783A1 publication Critical patent/AR045783A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica, producto y equipo farmacéutico que comprende un primer ingrediente activo que es un antagonista del receptor P2X7, y un segundo ingrediente activo que es una droga anti-inflamatoria no esteroide, para usar en el tratamiento de enfermedades inflamatorias. Reivindicación 14: Un proceso para la preparación de una composición farmacéutica como se define en cualquiera de las reivindicaciones 1 a 13 caracterizado porque comprende mezclar el primer ingrediente activo con el segundo ingrediente activo. Reivindicación 17: Un método para tratar una enfermedad inflamatoria caracterizado porque comprende administrar una cantidad efectiva para el uso terapéutico de una composición farmacéutica como se define en cualquiera de las reivindicaciones 1 a 13 para un paciente que lo necesita.
ARP040103356A 2003-09-18 2004-09-17 Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide AR045783A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination

Publications (1)

Publication Number Publication Date
AR045783A1 true AR045783A1 (es) 2005-11-16

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103356A AR045783A1 (es) 2003-09-18 2004-09-17 Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide

Country Status (20)

Country Link
US (1) US20070082930A1 (es)
EP (1) EP1663224A1 (es)
JP (1) JP2007505900A (es)
KR (1) KR20060086942A (es)
CN (1) CN1859911A (es)
AR (1) AR045783A1 (es)
AU (1) AU2004271886B2 (es)
BR (1) BRPI0414558A (es)
CA (1) CA2538416A1 (es)
IL (1) IL173913A0 (es)
IS (1) IS8396A (es)
MX (1) MXPA06002722A (es)
NO (1) NO20061662L (es)
NZ (1) NZ545964A (es)
RU (1) RU2338556C2 (es)
SE (1) SE0302488D0 (es)
TW (1) TW200526199A (es)
UY (1) UY28517A1 (es)
WO (1) WO2005025571A1 (es)
ZA (1) ZA200602260B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
WO2007098086A2 (en) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
JP5819846B2 (ja) * 2009-12-08 2015-11-24 バンダービルト ユニバーシティ 静脈摘出および自家移植のための改善された方法および組成物
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
WO2013082565A1 (en) * 2011-12-02 2013-06-06 Michael Kaleko Therapies for disorders of the cornea and conjunctiva
CA2959601A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Topical diclofenac sodium compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
RU2170730C2 (ru) * 1996-05-20 2001-07-20 Дарвин Дискавери Лимитед Хинолиновые карбоксамиды и фармацевтическая композиция на их основе
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JP2002541249A (ja) * 1999-04-09 2002-12-03 アストラゼネカ・アクチエボラーグ アダマンタン誘導体
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
EP1239856A1 (en) * 1999-12-22 2002-09-18 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US8058441B2 (en) * 2001-07-02 2011-11-15 N.V. Organon Tetrahydroquinoline derivatives
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO20061662L (no) 2006-04-11
UY28517A1 (es) 2005-04-29
EP1663224A1 (en) 2006-06-07
NZ545964A (en) 2009-09-25
IL173913A0 (en) 2006-07-05
AU2004271886A1 (en) 2005-03-24
BRPI0414558A (pt) 2006-11-07
TW200526199A (en) 2005-08-16
WO2005025571A1 (en) 2005-03-24
RU2006112423A (ru) 2007-11-10
AU2004271886B2 (en) 2008-03-20
CA2538416A1 (en) 2005-03-24
RU2338556C2 (ru) 2008-11-20
MXPA06002722A (es) 2006-06-06
CN1859911A (zh) 2006-11-08
ZA200602260B (en) 2007-07-25
US20070082930A1 (en) 2007-04-12
JP2007505900A (ja) 2007-03-15
IS8396A (is) 2006-04-03
SE0302488D0 (sv) 2003-09-18
KR20060086942A (ko) 2006-08-01

Similar Documents

Publication Publication Date Title
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
Kon et al. Non-surgical management of early knee osteoarthritis
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
JP2006501240A5 (es)
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
AR062167A1 (es) Sistema de administracion gastrorretentivo
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
RU2015103107A (ru) Комбинированная композиция
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CO2023011781A2 (es) Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
PA8615501A1 (es) Formulaciones farmaceuticas transdermicas
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Legal Events

Date Code Title Description
FB Suspension of granting procedure